Literature DB >> 3830718

Absolute bioavailability of mianserin tablets and solution in healthy humans.

C J Timmer, S Pourbaix, J P Desager, M Sclavons, C Harvengt.   

Abstract

A pharmacokinetic study with mianserin . HCl was performed in six healthy male subjects. The subjects were treated on different occasions intravenously with a constant-rate infusion of 5 mg mianserin. HCl in 1 h, orally with a single dose of 60 mg as two tablets of 30 mg each and with 60 mg as an oral solution. The wash-out period between treatments was 1 month. Blood samples were taken at predetermined times over a period of 120 h following dosing. The mianserin concentration in the plasma samples was determined and the results were pharmacokinetically analyzed. The intravenous data could be adequately described by a 3-compartment model and the oral data by a 2-compartment model, both with first-order transfer and elimination rate constants. The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h. The absolute bioavailability in terms of extent of absorption was 22 +/- 3% for the solution and 20 +/- 3% for the tablets. The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h. The mean absorption half-life for the solution was 0.43 +/- 0.13 h and for the tablets 0.39 +/- 0.11 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830718     DOI: 10.1007/BF03189759

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

1.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

2.  Curve fitting and modeling in pharmacokinetics: all programs are equal, but some programs are more equal than others.

Authors:  H P Wijnand; C J Timmer
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

3.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

4.  A pharmacokinetic study of mianserin.

Authors:  K P Maguire; T R Norman; G D Burrows; B A Scoggins
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Workshop on the clinical pharmacology and efficacy of mianserin.

Authors:  A Coppen; H Kopera
Journal:  Br J Clin Pharmacol       Date:  1978       Impact factor: 4.335

6.  Determining the probability of an important difference in bioavailability.

Authors:  B E Rodda; R L Davis
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

7.  Simplified method for determination of the tetracyclic antidepressant mianserin in human plasma using gas chromatography with nitrogen detection.

Authors:  J Vink; H J van Hal
Journal:  J Chromatogr       Date:  1980-01-11

8.  An aid to decision-making in bioequivalence assessment.

Authors:  H Fluehler; J Hirtz; H A Moser
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

9.  Symbols in pharmacokinetics.

Authors:  M Rowland; G Tucker
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

Review 10.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

View more
  4 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Variability in the elimination of mianserin in elderly patients.

Authors:  E J Begg; J R Sharman; J E Kidd; R Sainsbury; D W Clark
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 3.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

4.  The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study.

Authors:  Shuichi Nawata; Noriko Kohyama; Naoki Uchida; Satoshi Numazawa; Masayuki Ohbayashi; Yasuna Kobayashi; Masanori Iwata; Takanori Nakajima; Hiroshi Saito; Akira Izuka; Toshinori Yamamoto
Journal:  J Pharm Health Care Sci       Date:  2016-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.